Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo

Tao Liu,1,* Tingting Jia,2,* Xia Yuan,2 Cheng Liu,1 Jian Sun,1 Zhenhua Ni,1 Jian Xu,1 Xuhui Wang,2 Yi Yuan2 1Centralab, 2Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China *These authors contributed equally to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu T, Jia T, Yuan X, Liu C, Sun J, Ni Z, Xu J, Wang X, Yuan Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Polymeric Prodrug Breast Cancer Controlled Release Bufalin Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c8e9503fbe344efeb5e1a26c5d1eebc1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c8e9503fbe344efeb5e1a26c5d1eebc1
record_format	dspace
spelling	oai:doaj.org-article:c8e9503fbe344efeb5e1a26c5d1eebc12021-12-02T06:46:24ZDevelopment of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo1178-2013https://doaj.org/article/c8e9503fbe344efeb5e1a26c5d1eebc12016-05-01T00:00:00Zhttps://www.dovepress.com/development-of-octreotide-conjugated-polymeric-prodrug-of-bufalin-for--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Tao Liu,1,* Tingting Jia,2,* Xia Yuan,2 Cheng Liu,1 Jian Sun,1 Zhenhua Ni,1 Jian Xu,1 Xuhui Wang,2 Yi Yuan2 1Centralab, 2Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Development of polymeric prodrugs of small molecular anticancer drugs has become one of the most promising strategies to overcome the intrinsic shortcomings of small molecular anticancer drugs and improve their anticancer performance. Materials and methods: In the current work, we fabricated a novel octreotide (Oct)-modified esterase-sensitive tumor-targeting polymeric prodrug of bufalin (BUF) and explored its anticancer performance against somatostatin receptor 2 overexpressing breast cancer. Results: The obtained tumor-targeting polymeric prodrug of BUF, P(oligo[ethylene glycol] monomethyl ether methacrylate [OEGMA]-co-BUF-co-Oct), showed a nanosize dimension and controlled drug release features in the presence of esterase. It was demonstrated by in vitro experiment that P(OEGMA-co-BUF-co-Oct) showed enhanced cytotoxicity, cellular uptake, and apoptosis in comparison with those of free BUF. In vivo experiment further revealed the improved accumulation of drugs in tumor tissues and enhanced anticancer performance of P(OEGMA-co-BUF-co-Oct). Conclusion: Taken together, this study indicated that polymeric prodrug of BUF holds promising potential toward the treatment of somatostatin receptor 2 overexpressing breast cancer. Keywords: esterase responsive, controlled release, tumor targetingLiu TJia TYuan XLiu CSun JNi ZXu JWang XYuan YDove Medical PressarticlePolymeric ProdrugBreast CancerControlled ReleaseBufalinMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 2235-2250 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Polymeric Prodrug Breast Cancer Controlled Release Bufalin Medicine (General) R5-920
spellingShingle	Polymeric Prodrug Breast Cancer Controlled Release Bufalin Medicine (General) R5-920 Liu T Jia T Yuan X Liu C Sun J Ni Z Xu J Wang X Yuan Y Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
description	Tao Liu,1,* Tingting Jia,2,* Xia Yuan,2 Cheng Liu,1 Jian Sun,1 Zhenhua Ni,1 Jian Xu,1 Xuhui Wang,2 Yi Yuan2 1Centralab, 2Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Development of polymeric prodrugs of small molecular anticancer drugs has become one of the most promising strategies to overcome the intrinsic shortcomings of small molecular anticancer drugs and improve their anticancer performance. Materials and methods: In the current work, we fabricated a novel octreotide (Oct)-modified esterase-sensitive tumor-targeting polymeric prodrug of bufalin (BUF) and explored its anticancer performance against somatostatin receptor 2 overexpressing breast cancer. Results: The obtained tumor-targeting polymeric prodrug of BUF, P(oligo[ethylene glycol] monomethyl ether methacrylate [OEGMA]-co-BUF-co-Oct), showed a nanosize dimension and controlled drug release features in the presence of esterase. It was demonstrated by in vitro experiment that P(OEGMA-co-BUF-co-Oct) showed enhanced cytotoxicity, cellular uptake, and apoptosis in comparison with those of free BUF. In vivo experiment further revealed the improved accumulation of drugs in tumor tissues and enhanced anticancer performance of P(OEGMA-co-BUF-co-Oct). Conclusion: Taken together, this study indicated that polymeric prodrug of BUF holds promising potential toward the treatment of somatostatin receptor 2 overexpressing breast cancer. Keywords: esterase responsive, controlled release, tumor targeting
format	article
author	Liu T Jia T Yuan X Liu C Sun J Ni Z Xu J Wang X Yuan Y
author_facet	Liu T Jia T Yuan X Liu C Sun J Ni Z Xu J Wang X Yuan Y
author_sort	Liu T
title	Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
title_short	Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
title_full	Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
title_fullStr	Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
title_full_unstemmed	Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
title_sort	development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/c8e9503fbe344efeb5e1a26c5d1eebc1
work_keys_str_mv	AT liut developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT jiat developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT yuanx developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT liuc developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT sunj developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT niz developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT xuj developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT wangx developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT yuany developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo
_version_	1718399778194194432

Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo

Ejemplares similares